Sarah Bär, Raminta Kavaliauskaite, Tatsuhiko Otsuka, Yasushi Ueki, Jonas D Häner, George C M Siontis, Stefan Stortecky, Hiroki Shibutani, Fabrice Temperli, Christoph Kaiser, Juan F Iglesias, Robert Jan van Geuns, Joost Daemen, David Spirk, Thomas Engstrøm, Irene Lang, Stephan Windecker, Konstantinos C Koskinas, Sylvain Losdat, Lorenz Räber
BACKGROUND: Treatment with proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on top of statins leads to plaque regression and stabilisation. The effects of PCSK9 inhibitors on coronary physiology and angiographic diameter stenosis (DS%) are unknown. AIMS: This study aimed to investigate the effects of the PCSK9 inhibitor alirocumab on coronary haemodynamics as assessed by quantitative flow ratio (QFR) and DS% by three-dimensional quantitative coronary angiography (3D-QCA) in non-infarct-related arteries (non-IRA) among acute myocardial infarction (AMI) patients...
July 17, 2023: EuroIntervention